Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
IPO Year:
Exchange: NYSE
Website: zimmerbiomet.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $125.00 → $128.00 | Neutral → Overweight | Analyst |
| 9/10/2024 | Peer Perform | Wolfe Research | |
| 7/1/2024 | $140.00 → $115.00 | Overweight → Neutral | Piper Sandler |
| 5/30/2024 | $129.00 | Neutral | Goldman |
| 5/21/2024 | $150.00 | Hold → Buy | Argus |
| 1/4/2024 | $135.00 → $125.00 | Outperform → In-line | Evercore ISI |
| 10/20/2023 | $120.00 | Neutral | ROTH MKM |
| 8/28/2023 | $139.00 | Neutral → Buy | BTIG Research |
| 5/3/2023 | Underperform → Neutral | BofA Securities | |
| 4/11/2023 | $135.00 → $148.00 | In-line → Outperform | Evercore ISI |
Demonstrates Zimmer Biomet's Commitment to Investing in Higher GrowthEnd-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet's Financial Profile; Immediately Accretive to Revenue Growth and Accretive to Adjusted EPS within 24 Months of Deal Close WARSAW, Ind. and ENGLEWOOD, Colo., Jan. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, Inc. (NYSE:FNA), a leading medical device company focused exclusively on the foot and ankle orthopedic segment, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of common sto
WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may d
WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a compreh
WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind., Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral (upper shoulder bone) anatomy1-3 to optimize anatomical fit while maximizing preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio and integrates with Identity® Humeral Heads with Versa-Dial® Technology f
A Total Knee Replacement Alternative for Patients with Metal and/or Bone Cement Sensitivities WARSAW, Ind., Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® SoluTion™ Porous Plasma Spray (PPS®) Femur, a total knee implant component offering an alternative for patients with sensitivities to bone cement and/or metal. The Persona SoluTion PPS Femur features a porous coating for cementless fixation and leverages a proprietary surface treatment designed to enhance wear performance.1,2
WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement (PKR).1 The Oxford Cementless Partial Knee allows surgeons to perform a PKR with improved fixation,2 better long-term implant survival rate2,3 and improved efficiency in the operating room4 (OR) compared to the Oxford Cemented Partial Knee pro
WARSAW, Ind., Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024, with a fireside chat at 8:45 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio d
WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. "After the successful introduction of Persona Revision Knee in the United States and other markets, the CE Mark certification and commercial launch extends its availability significantly so that more surgeons have
Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster over
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously
Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform
Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously
Goldman initiated coverage of Zimmer Biomet with a rating of Neutral and set a new price target of $129.00
Argus upgraded Zimmer Biomet from Hold to Buy and set a new price target of $150.00
Evercore ISI downgraded Zimmer Biomet from Outperform to In-line and set a new price target of $125.00 from $135.00 previously
ROTH MKM initiated coverage of Zimmer Biomet with a rating of Neutral and set a new price target of $120.00
BTIG Research upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $139.00
BofA Securities upgraded Zimmer Biomet from Underperform to Neutral
Evercore ISI upgraded Zimmer Biomet from In-line to Outperform and set a new price target of $148.00 from $135.00 previously
WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may d
WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency1 basisThird quarter diluted earnings per share were $1.23; adjusted1 diluted earnings per share were $1.74Company updates 2024 financial guidance, reducing and narrowing range for full year outlookWARSAW, Ind., Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2024. The Company reported third quarter net sales of $1.824 billion, an increase of 4.0% over the prior year period, and an increase of 4.1% on a constant currency1 basis. Net earnings for the third quarter were $249.1 million, or $353.2 million on
WARSAW, Ind., Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do
WARSAW, Ind., Aug. 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024. The cash dividend of $0.24 per share is payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basisSecond quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidanceWARSAW, Ind., Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024. The Company reported second quarter net sales of $1.942 billion, an increase of 3.9% over the prior year period, and an increase of 5.6% on a constant curren
WARSAW, Ind., July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s
Presents Path for Compelling and Durable Topline Growth, Improved Operational Profitability and Increased Free Cash Flow Generation Details New Capital Allocation Priorities and Commitment to Strategic Diversification Announces Strategic Partnership with CBRE, the World's Largest Commercial Real Estate Services and Investment Firm, to Develop and Outfit Orthopedic Ambulatory Surgery Centers (ASC) in the U.S. WARSAW, Ind. and NEW YORK, May 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today hosted its 2024 Investor Day and provided an in-depth review of the Company's strategic priorities and long-range plan for growth and valu
WARSAW, Ind., May 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2024. The cash dividend of $0.24 per share is payable on or about July 31, 2024 to stockholders of record as of the close of business on June 26, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seaml
First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency1 basisFirst quarter diluted earnings per share were $0.84; adjusted1 diluted earnings per share were $1.94Company reiterates full-year 2024 financial guidanceWARSAW, Ind., May 2, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2024. The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over the prior year period, and an increase of 4.4% on a constant currency1 basis. Net earnings for the first quarter were $172.4 million, or $399.7 million on an adjusted1 basis.
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
CERT - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-A12B - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
424B5 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
FWP - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
424B5 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster over
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
WARSAW, Ind., Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President and Chief Executive Officer of the Hospital for Special Surgery (HSS), has been appointed to the Board, effective immediately. HSS has been recognized as a leading academic medical center focused on musculoskeletal health – it was ranked #1 in U.S. orthopedics hospitals for 14 years in a row by U.S. News & World Report and #1 in worldwide orthopedics hospitals by Newsweek for the past four consecutive years. Founded in 1863, HSS is the oldest orthopedics hospital in the U.S., performs more than 40,000 su
Chief Operating Officer Ivan Tornos Appointed President and CEO; Elected to the Board of Directors Chief Financial Officer Suketu (Suky) Upadhyay's Role Expands to CFO and EVP, Finance, Operations & Supply Chain Company Reaffirms Full-Year 2023 Financial Guidance WARSAW, Ind., Aug. 22, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served
Expanded Role Adds Responsibility for Environmental, Social and Governance (ESG) Strategy and Office of the CEO to Portfolio WARSAW, Ind., May 26, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE:ZBH) (SIX: ZBH), a global medical technology leader, today announced the appointment of Keri P. Mattox as Chief Communications and Administration Officer, reporting to President, Chief Executive Officer and Chairman Bryan Hanson. Ms. Mattox previously served as Senior Vice President, Investor Relations and Chief Communications Officer, and now adds responsibility for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CE
Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Accounting Officer WARSAW, Ind., May 16, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Paul Stellato as Vice President, Controller and Chief Accounting Officer. Prior to joining Zimmer Biomet, Mr. Stellato served as Vice President, Finance, Global Business Services at Xylem Inc. "With more than two decades of experience and a demonstrated track record of success in all areas of financial services, Paul will b